Relationship between plasma cell-free DNA changes and lysyl oxidase during the treatment and prognosis of canine transmissible venereal tumors.
Canine
Cell-free DNA
Liquid biopsies
Lysyl oxidase
Transmissible venereal tumor
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
21 Feb 2022
21 Feb 2022
Historique:
received:
01
11
2021
accepted:
09
02
2022
entrez:
22
2
2022
pubmed:
23
2
2022
medline:
7
4
2022
Statut:
epublish
Résumé
Transmissible venereal tumors (TVT) are a wide range of canine tumors for which there are no effective markers to monitor the therapeutic response in real-time. Circulating biomarkers can be valuable in early cancer diagnosis and prognosis. Accordingly, this study aimed to investigate the significance of the cell-free DNA (cfDNA) and cfDNA integrity index to monitor the response of TVTs to vincristine and compare them with lysyl oxidase activity. Plasma and sera were collected from fifteen male dogs within four weeks before drug administration. The analytical method was mainly based on the quantitative polymerase chain reaction (qPCR) technique for short and long cfDNAs and lysyl oxidase activity was measured in serum. The results of the cfDNA integrity index showed a significant (p < 0.05) difference in the baseline concentration compared to the second and third weeks (with cut-off values of 1.118 and 93.33% specificity). The cfDNA integrity index increased over time due to the reduction of short cfDNAs in the first week after treatment. Lysyl oxidase activity increased during the fourth week (p < 0.001), but there were no significant differences in the other weeks compared to the baseline. The ROC analysis of lysyl oxidase revealed high sensitivity (100%) and specificity (90%) on the second and third weeks compared to the baseline. Multivariate analysis between cfDNA integrity index and lysyl oxidase showed significant correlation (p < 0.05) only in baseline results. Overall, short cfDNA, the cfDNA integrity index, and lysyl oxidase activity can be proposed as diagnostic biomarkers and putative prognostic candidates in TVT patients. These biomarkers can be combined with cytology to quickly diagnose TVT.
Sections du résumé
BACKGROUND
BACKGROUND
Transmissible venereal tumors (TVT) are a wide range of canine tumors for which there are no effective markers to monitor the therapeutic response in real-time. Circulating biomarkers can be valuable in early cancer diagnosis and prognosis. Accordingly, this study aimed to investigate the significance of the cell-free DNA (cfDNA) and cfDNA integrity index to monitor the response of TVTs to vincristine and compare them with lysyl oxidase activity. Plasma and sera were collected from fifteen male dogs within four weeks before drug administration. The analytical method was mainly based on the quantitative polymerase chain reaction (qPCR) technique for short and long cfDNAs and lysyl oxidase activity was measured in serum.
RESULTS
RESULTS
The results of the cfDNA integrity index showed a significant (p < 0.05) difference in the baseline concentration compared to the second and third weeks (with cut-off values of 1.118 and 93.33% specificity). The cfDNA integrity index increased over time due to the reduction of short cfDNAs in the first week after treatment. Lysyl oxidase activity increased during the fourth week (p < 0.001), but there were no significant differences in the other weeks compared to the baseline. The ROC analysis of lysyl oxidase revealed high sensitivity (100%) and specificity (90%) on the second and third weeks compared to the baseline. Multivariate analysis between cfDNA integrity index and lysyl oxidase showed significant correlation (p < 0.05) only in baseline results.
CONCLUSIONS
CONCLUSIONS
Overall, short cfDNA, the cfDNA integrity index, and lysyl oxidase activity can be proposed as diagnostic biomarkers and putative prognostic candidates in TVT patients. These biomarkers can be combined with cytology to quickly diagnose TVT.
Identifiants
pubmed: 35189882
doi: 10.1186/s12917-022-03173-z
pii: 10.1186/s12917-022-03173-z
pmc: PMC8862336
doi:
Substances chimiques
Biomarkers, Tumor
0
Cell-Free Nucleic Acids
0
Protein-Lysine 6-Oxidase
EC 1.4.3.13
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
76Informations de copyright
© 2022. The Author(s).
Références
Cancer Lett. 2018 Mar 28;417:174-181
pubmed: 29309816
J Feline Med Surg. 2019 Feb;21(2):124-132
pubmed: 29529957
Arch Oral Biol. 2019 Jun;102:218-224
pubmed: 31078072
Tumour Biol. 2013 Apr;34(2):983-6
pubmed: 23269609
Crit Rev Clin Lab Sci. 2017 May;54(3):205-218
pubmed: 28393575
Genomics. 2019 Jul;111(4):906-912
pubmed: 29860031
Thorac Cancer. 2018 Jul;9(7):785-793
pubmed: 29766649
Biomol Detect Quantif. 2019 Mar 18;17:100087
pubmed: 30923679
Philos Trans R Soc Lond B Biol Sci. 2015 Jul 19;370(1673):
pubmed: 26056372
Vet Comp Oncol. 2007 Sep;5(3):145-55
pubmed: 19754786
Expert Opin Biol Ther. 2012 Jun;12 Suppl 1:S209-15
pubmed: 22594497
Mol Biol Rep. 2019 Oct;46(5):4909-4919
pubmed: 31264163
Vet Res Commun. 1996;20(1):71-81
pubmed: 8693703
Front Vet Sci. 2021 Jul 08;8:704835
pubmed: 34307538
Surg Oncol. 2017 Dec;26(4):395-401
pubmed: 29113658
Cell Struct Funct. 2012;37(1):75-80
pubmed: 22453058
Am J Vet Res. 2013 Feb;74(2):216-23
pubmed: 23363345
Oncotarget. 2018 May 11;9(36):24514-24524
pubmed: 29849957
PLoS One. 2017 Jan 12;12(1):e0169454
pubmed: 28081183
Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1595-1602
pubmed: 28830871
J Vet Med A Physiol Pathol Clin Med. 2005 Sep;52(7):366-70
pubmed: 16109105
Semin Oncol. 2017 Oct;44(5):330-346
pubmed: 29580435
PLoS One. 2020 Aug 31;15(8):e0236228
pubmed: 32866177
Cancer Res. 2003 Jul 15;63(14):3966-8
pubmed: 12873992
Sports Med. 2012 Jul 1;42(7):565-86
pubmed: 22694348
J Trace Elem Med Biol. 2021 May;65:126715
pubmed: 33465739
Int J Mol Sci. 2020 Dec 21;21(24):
pubmed: 33371259
Int J Clin Oncol. 2020 Jul;25(7):1308-1317
pubmed: 32277394
Int J Mol Sci. 2016 Dec 29;18(1):
pubmed: 28036074
J Vet Med Sci. 2014 Dec;76(12):1549-53
pubmed: 25649934
J Vet Diagn Invest. 2019 Nov;31(6):836-843
pubmed: 31585514
Cell Mol Biol (Noisy-le-grand). 2019 Jul 31;65(6):64-72
pubmed: 31472049
Int J Mol Sci. 2020 Sep 17;21(18):
pubmed: 32957662
Vet Res Commun. 2000 Dec;24(8):545-56
pubmed: 11305746
PLoS One. 2013 Sep 30;8(9):e75485
pubmed: 24098698
Mol Oncol. 2021 Sep;15(9):2401-2411
pubmed: 33934494
Vet Comp Oncol. 2010 Mar;8(1):50-5
pubmed: 20230581
BMC Cancer. 2014 Jul 22;14:532
pubmed: 25052686
Future Oncol. 2014;10(9):1709-17
pubmed: 25145437
Sci Rep. 2021 Jan 13;11(1):877
pubmed: 33441840